Skip to content

We are an innovative and ambitious med-tech company that is working tirelessly to improve the quality of life of patients suffering from a variety of Vertebral Fractures

Our Story​

Amber Implants is a VC-backed med-tech company started its operation in 2019.

The founders of the company, Dr. Banafsheh Sajadi and Dr. Mohammad Ahmadi have accomplished their Ph.D. degrees at Delft University of Technology and started developing innovative and creative orthopaedic implants since then. The company is now consisting of a (rapidly expanding) young and ambitious team that works on the developments of orthopaedic products. Also, a well-experienced and internationally-known team are already planning for commercialization of the product in the next stage. The company is working according to ISO 13485 and FDA guidelines for the manufacturing of the medical devices.

Our first product, VCFix® Spinal System has passed all pre-clinical validation and has started the clinical phase in 2023.

Our mission

Quality

At Amber Implants we are dedicated to deliver high quality medical products and services to improve patients’ quality of life.

Commitment

Amber Implants is committed to and accountable for advancing diversity, equity, and inclusion in all of its forms.

Team

​At Amber Implants we prioritize to build and maintain a healthy and equally treated organization with highly qualified employees.

Our team

Banafsheh
Sajadi

CO-FOUNDER, CEO​

Mohammad
Ahmadi

CO-FOUNDER, CTO

Vincent
Gardès

CHAIR OF THE BOARD

Looking for all the employees of Amber Implants? Check out our LinkedIn page.

Interested in joining our team? Check our available positions or send an open application.

Company timeline

2018
Company launch

Launching the company and recieving seed fund raising.

2019
Collaborations

Our company was involved with more than 4 European level and national level researches and collaborations with 20 research partners.

2020
VCFix® spinal system

Official kick off of the VCFix® project, including feasibility studies and receiving breakthrough designation

2021
Series A fundraising

Receiving the series A fundraising.

2022
Finishing the pre-clinical

Finishing the pre-clinical activities and  regulatory phase.

2023
Current status
Clinical

First clinical trials